Details

Autor(en) / Beteiligte

• Weggen, Sascha
• Eriksen, Jason L.
• Sagi, Sarah A.
• Pietrzik, Claus U.
• Golde, Todd.E.
• Koo, Edward H.

Titel

Aβ42-lowering Nonsteroidal Anti-inflammatory Drugs Preserve Intramembrane Cleavage of the Amyloid Precursor Protein (APP) and ErbB-4 Receptor and Signaling through the APP Intracellular Domain

Ist Teil von

• The Journal of biological chemistry, 2003-08, Vol.278 (33), p.30748-30754

Ort / Verlag

Elsevier Inc

Erscheinungsjahr

2003

Link zum Volltext

Quelle

Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals

Beschreibungen/Notizen

• Epidemiological studies indicate that long term use of nonsteroidal anti-inflammatory drugs (NSAIDs) confers protection from Alzheimer's disease, and some NSAIDs were shown to specifically decrease production of the amyloidogenic Aβ42 peptide, most likely by direct modulation of γ-secretase activity. In contrast to γ-secretase inhibitors, Aβ42-lowering NSAIDs do not impair S3 cleavage in the NOTCH receptor and release of the NOTCH intracellular domain, a finding with conceptual implications for the development of safer drugs targeting Aβ production through γ-secretase modulation. Intramembrane cleavage and release of an intracellular signaling domain has recently been demonstrated in a number of additional γ-secretase substrates. We now show in cell-based assays that intramembrane cleavage of APP and ErbB-4 receptor is not impaired by the Aβ42-lowering NSAIDs, sulindac sulfide and ibuprofen. Generation of the APP intracellular domain (AICD) was further not inhibited in a cell-free assay at concentrations far exceeding those effective in reducing Aβ42 production. Closer inspection of AICD signaling showed that stabilization of the AICD peptide by FE65 and AICD-mediated transcription were also retained at Aβ42-lowering concentrations. These results demonstrate that S3-like/intramembrane cleavage is preserved by Aβ42-lowering NSAIDs in at least three substrates of γ-secretase APP, ErbB-4, and NOTCH and underline the striking specificity by which these drugs target Aβ42 production.